Accuray(ARAY)
Focus: Accuray is a public oncology-focused medical device company specializing in directed radiation therapy platforms for cancer treatment. With $447M in FY2025 revenue, they operate as a mid-cap biotech with established commercial infrastructure.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
25+9 this month
Growing — net +9 jobs in 30d
20 jobs added vs 11 removed. Steady team buildout.
Should You Work at Accuray?
AI assessmentAccuray offers stability and technical depth for engineers in radiation oncology, but profitability challenges and modest hiring activity may limit career acceleration compared to higher-growth peers.
Why Work Here
- Established $447M revenue base with 4% YoY growth signals a stable, operationally mature organization with proven market adoption
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Late-stage
3 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$447M
Key Products
Stereotactic Radiosurgery
Growing
Growth
Lead program in Phase 3 with 7 active trials; represents core commercial validation of Accuray's radiation platform in oncology.
Pipeline & Clinical Trials
Help build intelligence for Accuray
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.